Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
8.63
+0.53 (6.54%)
At close: Aug 1, 2025, 4:00 PM
8.50
-0.13 (-1.51%)
After-hours: Aug 1, 2025, 6:40 PM EDT
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 15 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $20.07, which forecasts a 132.56% increase in the stock price over the next year. The lowest target is $10 and the highest is $36.
Price Target: $20.07 (+132.56%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 | 5 | 6 |
| Buy | 4 | 4 | 5 | 5 | 7 | 8 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 13 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $24 → $21 | Buy | Maintains | $24 → $21 | +143.34% | Jul 31, 2025 |
| Oppenheimer | Oppenheimer | Buy Initiates $24 | Buy | Initiates | $24 | +178.10% | Jul 28, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $16 | Strong Buy | Initiates | $16 | +85.40% | Jul 16, 2025 |
| Wedbush | Wedbush | Buy Reiterates $18 | Buy | Reiterates | $18 | +108.57% | Jun 23, 2025 |
| Raymond James | Raymond James | Buy Initiates $14 | Buy | Initiates | $14 | +62.22% | Jun 11, 2025 |
Financial Forecast
Revenue This Year
59.01M
from 108.30M
Decreased by -45.51%
Revenue Next Year
61.70M
from 59.01M
Increased by 4.55%
EPS This Year
-1.08
from -0.70
EPS Next Year
-1.09
from -1.08
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 98.7M | 126.0M | 402.2M | ||
| Avg | 59.0M | 61.7M | 133.0M | ||
| Low | 34.3M | n/a | 32.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -8.9% | 113.5% | 551.8% | ||
| Avg | -45.5% | 4.6% | 115.6% | ||
| Low | -68.3% | - | -47.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.90 | -0.84 | 0.27 | ||
| Avg | -1.08 | -1.09 | -0.71 | ||
| Low | -1.23 | -1.39 | -1.27 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.